Search

Search Constraints

You searched for: Author/Creator Piermatteo, L.

Search Results

1. A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases. (February 2019)

2. An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets. Issue 1 (16th February 2017)

4. HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B. Issue 1 (February 2018)

5. HDV epidemic in Central Italy is stable over the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 inducing different inflammatory stimuli. (March 2023)

6. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability: Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?. Issue 1 (16th February 2017)

7. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. (February 2019)

8. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression. (February 2020)

9. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting. (February 2020)

10. The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism. (February 2019)